MedTrace Logo

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

NCT00477529 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2019-11-22

No results posted yet for this study

Summary

To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008 given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.

Conditions

  • Hormone Refractory Prostate Cancer

Interventions

DRUG

ABI-008

nab-docetaxel

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • John C Araujo, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-01
Primary Completion
2011-06-02
Completion
2011-06-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00477529 on ClinicalTrials.gov